APR-246

TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax

TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax

Kunhwa Kim • 17 Dec 2020

Using an animated patient’s guide to improve understanding of MDS

Using an animated patient’s guide to improve understanding of MDS

David Sallman • 10 Dec 2020

Promising therapies on the horizon for MDS

Promising therapies on the horizon for MDS

Maria Teresa Voso • 29 Jan 2021

Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246

Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246

Valeria Santini • 25 Jan 2021

Novel therapies in the future of MDS treatment

Novel therapies in the future of MDS treatment

Felicitas Thol • 22 Jan 2021

APR-246 combination treatments in TP53-mutant R/R NHLs

APR-246 combination treatments in TP53-mutant R/R NHLs

Meghan Thompson • 8 Dec 2020

The 2020 highlights in MDS

The 2020 highlights in MDS

Thomas Cluzeau • 30 Sep 2020

MDS: state of the art in Europe

MDS: state of the art in Europe

Valeria Santini • 10 Sep 2020

Advances and challenges in AML treatment

Advances and challenges in AML treatment

Naval Daver • 3 Sep 2020

APR-246 in TP53 mutated MDS and AML

APR-246 in TP53 mutated MDS and AML

David Sallman • 3 Sep 2020

The role of venetoclax in older patients with AML

The role of venetoclax in older patients with AML

Andrew Wei • 25 Jun 2020

APR-246 with azacitidine for p53 mutated MDS and AML

APR-246 with azacitidine for p53 mutated MDS and AML

Thomas Cluzeau • 12 Jun 2020

Immuno-oncology paving the way in MDS

Immuno-oncology paving the way in MDS

Uma Borate • 1 Jun 2020

Azacitidine in the treatment of MDS

Azacitidine in the treatment of MDS

David Steensma • 5 Mar 2020

Novel drug targets for MDS

Novel drug targets for MDS

Stephen Nimer • 5 Mar 2020

APR-246 and azacitidine in TP53m MDS and AML

APR-246 and azacitidine in TP53m MDS and AML

Thomas Cluzeau • 7 Dec 2019